Financial Performance - Earnings from continuing operations were $(426) million ($(0.81) per diluted share) in Q3 2025, a decline from $111 million ($0.31 per diluted share) in Q3 2024 [169]. - Adjusted EBITDA from continuing operations was $859 million in Q3 2025, representing a 28% sequential increase [173]. - Net sales for Q3 2025 reached $6.22 billion, a 1% increase from Q2 2025 and a 56% increase from Q3 2024, driven primarily by higher sales prices [203]. - Diluted earnings per share from continuing operations for Q3 2025 was $(2.09), a decrease from $0.42 in Q2 2025 and $0.14 in Q3 2024 [201]. - An income tax benefit of $250 million was recorded for Q3 2025, resulting in an effective income tax rate of 37% [210]. - The Company reported cash provided by operations of $793 million for the first nine months of 2025, down from $1.3 billion in the same period of 2024, primarily due to significant payments impacting cash flow by approximately $670 million [225]. Business Divestitures and Impairments - The company recorded a $1.0 billion impairment related to the divestment of the Global Cellulose Fibers business, expected to close by year-end 2025 [173][178]. - The divestiture of the Global Cellulose Fibers business was agreed for $1.5 billion, with preferred stock consideration of $190 million [178]. - The Company announced a definitive agreement to sell its Global Cellulose Fibers business, with all related operating results classified as Discontinued Operations [215]. - Discontinued operations included net special items expense of $1.0 billion for Q3 2025, compared to $1 million and $15 million for Q3 2024 and Q2 2025, respectively [216]. Cost Management and Operational Efficiency - The company is focusing on cost management and operational efficiency, including outsourcing a portion of its North American IT services [182]. - The third quarter results reflect improved price realization and cost management, contributing to strategic wins across various customer segments [171][172]. - The company anticipates lower adjusted EBITDA from continuing operations in PS NA for Q4 2025 due to reduced volumes and increased maintenance costs [174]. Capital Expenditures and Cash Flow - Capital expenditures totaled $1.2 billion in the first nine months of 2025, compared to $661 million in the same period of 2024, with full-year 2025 capital expenditures expected to be approximately $1.8 billion to $1.9 billion [227]. - Free cash flow for the first nine months of 2025 was $(414) million, compared to $620 million for the same period in 2024 [198]. - Cash used for investment activities totaled $(478) million in the first nine months of 2025, an improvement from $(634) million in the same period of 2024 [226]. Debt and Financing - The Company maintained a long-term credit rating of BBB (stable outlook) and Baa2 (stable outlook) by S&P and Moody's, respectively, as of September 30, 2025 [229]. - The Company had no borrowings outstanding under its commercial paper program or USD denominated committed bank facility as of September 30, 2025 [228]. - The Company amended its £1.25 billion credit facility agreement to align with International Paper's existing credit facilities, allowing for additional flexibility for potential reorganization of subsidiaries [233]. - As of September 30, 2025, the Company had approximately $1.2 billion (€1.035 billion) borrowings outstanding under the credit facility, with no restrictive covenants other than compliance with negative covenants [233]. - The Company continues to rely on debt and capital markets for long-term funding not provided by operating cash flows, guided by capital structure planning objectives [237]. Shareholder Returns - Cash dividend payments totaled $733 million for the first nine months of 2025, compared to $482 million for the same period in 2024, maintaining dividends at $1.3875 per share [240]. - During the first nine months of 2025, the Company used 3.6 million shares of treasury stock for incentive plans and acquired 1.1 million shares related to restricted stock tax withholdings, totaling $64 million in payments [238]. - The Company has approximately $2.96 billion of shares of common stock remaining authorized for purchase under its share repurchase program as of September 30, 2025 [238]. Economic and Market Conditions - The company is navigating a complex macroeconomic landscape, with factors such as elevated interest rates and shifting consumer behavior impacting industrial production [183]. - The enactment of the One Big Beautiful Bill Act introduced tax policy changes, which the company is evaluating for potential implications on its financial statements [185].

Financial Performance - Total revenues for the three months ended September 30, 2025, were $311,455 thousand, slightly up from $309,588 thousand in the same period of 2024, reflecting a 0.6% increase[17]. - Net income for the three months ended September 30, 2025, was $163,497 thousand, down from $180,669 thousand in 2024, indicating a decrease of 9.5%[19]. - The company reported a total comprehensive income of $226,054 thousand for the three months ended September 30, 2025, compared to $314,990 thousand in 2024, a decrease of 28.2%[19]. - Basic net income per common share for the three months ended September 30, 2025, was $1.11, down from $1.16 in 2024, a decline of 4.3%[17]. - Net income for the nine months ended September 30, 2025, was $497,083, compared to $525,330 for the same period in 2024, reflecting a decrease of approximately 5.4%[24]. - The company reported comprehensive income of $662,753 for the nine months ended September 30, 2025, compared to $653,746 for the same period in 2024, showing a slight increase of about 1.6%[22]. Assets and Liabilities - Total assets increased to $6,876,443 thousand as of September 30, 2025, up from $6,521,531 thousand at December 31, 2024, representing a growth of 5.4%[15]. - Total liabilities increased to $1,559,157 thousand as of September 30, 2025, from $1,525,435 thousand at December 31, 2024, reflecting a growth of 2.2%[15]. - Total equity rose to $5,317,286 thousand as of September 30, 2025, compared to $4,996,096 thousand at December 31, 2024, an increase of 6.4%[15]. - Cash and cash equivalents at the end of the period on September 30, 2025, were $543,577, down from $673,363 at the end of September 2024, a decrease of about 19.2%[24]. Investment Income and Losses - Net investment income for the three months ended September 30, 2025, was $68,611 thousand, up from $61,056 thousand in 2024, representing an increase of 12.5%[17]. - Net investment income for the nine months ended September 30, 2025, was $197,532, an increase from $177,940 in 2024, indicating a growth of approximately 11%[41]. - For the three months ended September 30, 2025, net investment losses amounted to $2,834,000, compared to losses of $1,243,000 in the same period of 2024, reflecting a significant increase in losses[42]. - For the nine months ended September 30, 2025, net investment losses totaled $13,420,000, compared to $15,640,000 for the same period in 2024, indicating a decrease in losses year-over-year[42]. Insurance and Loss Reserves - Total loss reserves as of September 30, 2025, amounted to $572.1 million, an increase from $524.7 million as of December 31, 2024[105]. - For the nine months ended September 30, 2025, losses and LAE incurred related to insured events of the current accident year were $221 million, compared to $212 million for the same period in 2024[110]. - The gross loss reserves for domestic mortgage insurance increased to $566.9 million as of September 30, 2025, from $520.0 million at the end of 2024[105]. - The company recorded favorable reserve adjustments of $140 million primarily on prior accident year reserves due to improved cure performance of delinquencies[110]. Shareholder Activities - The company repurchased common stock totaling $255,377 during the nine months ended September 30, 2025, compared to $169,321 in the same period of 2024, reflecting an increase of approximately 50.9%[24]. - Cash dividends paid to Genworth were $25.1 million for the three months ended September 30, 2025, and $73.4 million for the nine months ended September 30, 2025[142]. - Total dividends declared and paid per common share for 2025 was $0.605, down from $0.715 in 2024[158]. - During Q3 2025, the company repurchased 2,824,499 shares at an average price of $37.23 per share, compared to 2,096,329 shares at $34.04 per share in Q3 2024[155]. Market Conditions and Performance Metrics - The U.S. mortgage origination market remained slow due to elevated mortgage rates, impacting housing affordability[166]. - The loss ratio for Q3 2025 was 15%, up from 5% in Q3 2024, with a reserve release of $45 million in Q3 2025 compared to $65 million in Q3 2024[172][192]. - The primary persistency rate remained stable at 83% for both Q3 2025 and Q3 2024, indicating strong retention of in-force policies[170]. - New insurance written (NIW) for Q3 2025 was $14.0 billion, representing a 3% increase compared to Q3 2024[170].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-21184 MICROCHIP TECHNOLOGY INCORPORATED $0.001 par value per share (Exact Name of Registrant as Specifi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-21184 MICROCHIP TECHNOLOGY INCORPORATED (Exact Name of Registrant as Specified in Its Charter) (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Delaware 86-3988281 (State or other ...

For Immediate Release Kura Sushi USA Announces Fiscal Fourth Quarter and Fiscal Year 2025 Financial Results Irvine, CA. November 6, 2025 – Kura Sushi USA, Inc. ("Kura Sushi" or the "Company") (NASDAQ: KRUS), a technology- enabled Japanese restaurant concept, today announced financial results for the fiscal fourth quarter and fiscal year ended August 31, 2025. Fiscal Fourth Quarter 2025 Highlights *Adjusted net income, Restaurant-level operating profit and Adjusted EBITDA are non-GAAP measures and are define ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Emplo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to ________ Commission file number: 001-35593 HOMETRUST BANCSHARES, INC. (Exact name of registrant as specified in its charter) Maryland 45-5055422 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission file number 001-39510 STEPSTONE GROUP INC. (Exact name of Registrant as specified in its charter) D ...

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 Exhibit 99.1 vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousan ...